| 0.41 0 (0%) | 03-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.6 |
1-year : | 0.7 |
| Resists | First : | 0.51 |
Second : | 0.6 |
| Pivot price | 0.31 |
|||
| Supports | First : | 0.21 |
Second : | 0.03 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.31 |
| MA(100) : | 0.55 |
MA(250) : | 3.76 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.6 |
D(3) : | 61.8 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 13.59 | Low : | 0.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CLSD ] has closed below upper band by 44.1%. Bollinger Bands are 94.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 109 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.32 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.31 - 0.32 | 0.32 - 0.32 |
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Tue, 25 Nov 2025
Clearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process - VisionMonday.com
Fri, 14 Nov 2025
CLSD: Cash shortfall, paused R&D, and strategic review signal urgent going concern risk - TradingView
Fri, 14 Nov 2025
Clearside Biomedical, Inc. SEC 10-Q Report - TradingView
Fri, 15 Aug 2025
Clearside Biomedical, Inc. (CLSD) Stock Price, News, Quote & History - Yahoo! Finance Canada
Thu, 24 Apr 2025
Clearside Biomedical (CLSD) Stock Price, News & Analysis - Stock Titan
Sun, 28 May 2017
Clearside Biomedical, Inc. (CLSD) stock price, news, quote and history - Yahoo Finance Australia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 4.54e+006 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.263e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 502.4 % |
| Return on Equity (ttm) | -70.4 % |
| Qtrly Rev. Growth | 3.33e+006 % |
| Gross Profit (p.s.) | -45.03 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 1.63687e+006 |
| Qtrly Earnings Growth | -5.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 141010 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|